Inhibitory effect of human telomerase antisense oligodeoxyribonucleotides on the growth of gastric cancer cell lines in variant tumor pathological subtype

World Journal of Gastroenterology

Volumn 11, Issue 15, 2005, Pages 2230-2237

  Ye, Jing ^a   Wu, Yun Lin ^a   Zhang, Shu ^a   Chen, Zi ^b   Guo, Li Xia ^c   Zhou, Ruo Yu ^c   Xie, Hong ^c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

MKN 28; MKN 45; SGC 7901

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; HUMAN TELOMERASE ANTISENSE OLIGODEOXYRIBONUCLEOTIDE; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NICK END LABELING; PROTEIN EXPRESSION; STOMACH CANCER; TELOMERIC REPEAT AMPLIFICATION PROTOCOL; CELL DIFFERENTIATION; CELL DIVISION; GENE THERAPY; METHODOLOGY; PATHOLOGY; STOMACH TUMOR; TUMOR CELL LINE;

APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; GENE THERAPY; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; STOMACH NEOPLASMS;

EID: 18744413910     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i15.2230     Document Type: Article

References (22)

1. Greenwood MJ, Lansdorp PM. Telomeres, telomerase, and hematopoietic stem cell biology. Arch Medi Res 2003; 34: 489-495
2. Karayan-Tapon L, Menet E, Guilhot J, Levillain P, Larsen CJ, Kraimps JL. Topoisomerase H alpha and telomerase expression in papillary thyroid carcinomas. Eur J Surg Oncol 2004; 30: 73-79
3. Shen ZY, Xu LY, Li EM, Cai WJ, Chen MH, Shen J, Zeng Y. Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell. World J Gastroenterol 2002; 8: 357-362
4. Usselmann B, Newbold M, Morris AG, Nwokolo CU. Telomerase activity and patient survival after surgery for gastric and oesophageal cancer. Eur J Gastroenterol Hepatol 2001; 13: 903-908
5. Tang DQ. Oncology of the Time. 2nd edition. Shanghai: Shanghai Medical University 2000: 695
6. Zhang RG, Wang XW, Yuan JH, Guo LX, Xie H. Using a nonradioisotopic, quantitative TRAP-based method detecting telomerase activities in human hepatoma cells. Cell Res 2000; 10: 71-77
7. Zhang RG, Wang XW, Yuan JH, Xie H. Human hepatoma cell telomerase activity inhibition and cell cycle modulation by its RNA component antisense oligodeoxyribonucleotides. Acta Pharmacol Sin 2000; 21: 742-746
8. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Cryaznov S, Moore MA. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004; 103: 258-266
9. Yatabe N, Kyo S, Kondo S, Kanaya T, Wang Z, Maida Y, Takakura M, Nakamura M, Tanaka M, Inoue M. 2-5A antisense therapy directed against human telomerase RNA inhibits telomerase activity and induces apoptosis without telomere impairment in cervical cancer cells. Cancer Gene Ther 2002; 9: 624-630
10. Kubo T, Bakalova R, Ohba H, Fujii M. Antisense effects of DNA-peptide conjugates. Nucleic Acids Res Suppl 2003; 3: 179-180
11. Kosciolek BA, Kalantidis K, Tabler M, Rowley PT. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2003; 2: 209-216
12. Jansen B, Zangemeister-Wittke U. Antisense therapy for cancer-the time of truth. Lancet Oncol 2002; 11: 672-683
13. Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wienties MG, Au JL. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003; 63: 579-585
14. Rezler EM, Bearss DJ, Hurley LH. Telomere inhibition and telomere disruption as processes for drug targeting. Annu Rev Pharmacol Toxicol 2003; 43: 359-379
15. Odago FO, Gerson SL. Telomerase inhibition and telomere erosion: a two-pronged strategy in cancer therapy. Trends Pharmacol Sci 2003; 24: 328-331
16. De Caceres II, Frolova N, Varkonyi RJ, Dulaimi E, Meropol NJ, Broccoli D, Cairns P. Telomerase is frequently activated in tumors with microsatellite unstability. Cancer Biol Ther 2004; 3: 289-292
17. Fukazawa T, Maeda Y, Sladek FM, Owen-Schaub LB. Development of a cancer-targeted tissue-specific promoter system. Cancer Res 2004; 64: 363-369
18. Kondo S, Tanaka Y, Kondo Y. Antisense telomerase treatment: induction of two distince pathways, apoptosis and differentiation. FASEB J 1998; 12: 801-810
19. Naka K, Yokozaki H, Yasui W, Tahara H, Tanara E. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines. Biochem Biophys Res Commun 1999; 255: 753-758
20. Taggart AK, Teng SC, Zakian VA. Est1p as a cell cycle-regulated activator of telomere-bound telomerase. Science 2002; 297: 1023-1026
21. Wong SC, Yu H, Moochhala SM, So JB. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Anticancer Res 2003; 23: 465-469
22. Shammas MA, Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004; 10: 770-776